myelodysplastic syndromes (MDS) | Page 154 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors

Author(s): 
Steensma DP
Primary Author: 
Steensma DP
Journal Title: 
Curr Hematol Malig Rep
Original Publication Date: 
Sep 2012

Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic

Bone Marrow Disease(s): 

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

Author(s): 
Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL
Primary Author: 
Bejar R
Journal Title: 
J Clin Oncol
Original Publication Date: 
Aug 2012

PURPOSE A subset of patients with

Bone Marrow Disease(s): 

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

Author(s): 
Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP
Primary Author: 
Sekeres MA
Journal Title: 
Blood
Original Publication Date: 
Aug 2012

Bone Marrow Disease(s): 

Rationale for the Clinical Application of Flow Cytometry in Patients with Myelodysplastic Syndromes

Author(s): 
van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E
Primary Author: 
van de Loosdrecht AA
Journal Title: 
Leuk Lymphoma
Original Publication Date: 
Aug 2012

An international working group within the European LeukemiaNet gathered, aiming to determine the role of

Bone Marrow Disease(s): 

The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes

Author(s): 
Wang R, Gross CP, Frick K, Xu X, Long J, Raza A, Galili N, Zikria J, Guan Y, Ma X
Primary Author: 
Wang R
Journal Title: 
Leuk Res
Original Publication Date: 
Aug 2012

During 2004-2006, two hypomethylating agents (HMAs) were approved for the treatment of

Bone Marrow Disease(s): 
Share with addtoany.com.